Page last updated: 2024-08-24

aromasil and Atypical Ductal Hyperplasia

aromasil has been researched along with Atypical Ductal Hyperplasia in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (25.00)	29.6817
2010's	3 (75.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Allevi, G; Andreis, D; Bottini, A; Buffa, FM; Byrne, D; Cummings, M; Deb, S; Ferrero, G; Fox, SB; Generali, D; Harris, AL; Lakhani, SR; Martinotti, M; Reid, LE; Taylor, M	1
Aktas, B; Hofstatter, EW; Pusztai, L; Sorkin, M	1
Auboeuf, D; Bénès, V; Dalenc, F; Gratadou, L; Lacroix-Triki, M; Maillot, G; Millevoi, S; Pierredon, S; Roché, H; Schmidt, S; Vagner, S	1
Alés-Martínez, JE; Cheung, AM; Chlebowski, RT; Fabian, CJ; Farmer, P; Garber, JE; Gelmon, KA; Goss, PE; Ingle, JN; Johnson, KC; Martin, LW; Maunsell, E; McTiernan, A; Pujol, P; Richardson, H; Robbins, J; Sarto, GE; Tu, D; Wactawski-Wende, J; Winquist, E	1

Trials

3 trial(s) available for aromasil and Atypical Ductal Hyperplasia

Article	Year
COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment. British journal of cancer, 2014, Jul-08, Volume: 111, Issue:1 Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Celecoxib; Cohort Studies; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Prognosis; Pyrazoles; Sulfonamides; Survival Analysis	2014
Widespread estrogen-dependent repression of micrornas involved in breast tumor cell growth. Cancer research, 2009, Nov-01, Volume: 69, Issue:21 Topics: Androstadienes; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Northern; Blotting, Western; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Cell Proliferation; Estrogen Antagonists; Estrogens; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Pilot Projects; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tamoxifen; Treatment Outcome	2009
Exemestane for breast-cancer prevention in postmenopausal women. The New England journal of medicine, 2011, Jun-23, Volume: 364, Issue:25 Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Double-Blind Method; Female; Follow-Up Studies; Humans; Incidence; Middle Aged; Neoplasm Invasiveness; Postmenopause; Quality of Life; Risk Factors	2011

Other Studies

1 other study(ies) available for aromasil and Atypical Ductal Hyperplasia

Article	Year
Uptake of exemestane chemoprevention in postmenopausal women at increased risk for breast cancer. European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP), 2016, Volume: 25, Issue:1 Topics: Aged; Androstadienes; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging; Postmenopause; Prognosis; Retrospective Studies; Risk Assessment; Selective Estrogen Receptor Modulators	2016

Article

Year

Uptake of exemestane chemoprevention in postmenopausal women at increased risk for breast cancer.

European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP), 2016, Volume: 25, Issue:1

Topics: Aged; Androstadienes; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging; Postmenopause; Prognosis; Retrospective Studies; Risk Assessment; Selective Estrogen Receptor Modulators

2016